Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to provide Belzutifan to patients with von Hippel-Lindau disease.

The National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether new medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits. The NICE has published final draft guidance that recommends belzutifan for treating tumours associated with von Hippel-Lindau disease subject to a managed access agreement. Belzutifan is now available to eligible patients through the Cancer Drugs Fund in line with the NICE’s final draft recommendations, ahead of the publication of the NICE’s final guidance.